denileukin diftitox (E7777)
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Jul 1, 2011 → Jan 1, 2016
NCT ID
NCT01401530About denileukin diftitox (E7777)
denileukin diftitox (E7777) is a phase 1 stage product being developed by Eisai for Peripheral T-Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01401530. Target conditions include Peripheral T-Cell Lymphoma.
What happened to similar drugs?
8 of 20 similar drugs in Peripheral T-Cell Lymphoma were approved
Approved (8) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01401530 | Phase 1 | Completed |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma